Carbamazepine is not a substrate for p-glycoprotein

A. Owen, M. Pirmohamed, J.N.A. Tettey, P. Morgan, D. Chadwick, B.K. Park

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

Aims to determine whether the anticonvulsant carbamazepine (CBZ), a known CYP3A4 substrate, is also a substrate for the multidrug efflux transporter P-glycoprotein (Pgp). The role of Pgp in the transport of CBZ was assessed in three systems: (a) in mdr1a/1b(−/−) and wild-type mice after administration of 2 mg kg−1 and 20 mg kg−1, which served as a model for brain penetration; (b) in Caco-2 cells, an in vitro model of the intestinal epithelium that is known to express high Pgp levels; and (c) by flow cytometry in lymphocytes using rhodamine 123, a fluorescent substrate for PgP. Brain penetration of both doses of CBZ at 1 h and 4 h was comparable in wild-type and mdr1a/1b(−/−) mice. Transport across the Caco-2 cell monolayer was Pgp-independent, and was not affected by the Pgp inhibitor PSC-833. CBZ had no effect on rhodamine 123 efflux from lymphocytes, in contrast to verapamil, which increased fluorescence intensity fivefold. CBZ is not a substrate for Pgp. Its efficacy is unlikely to be affected by Pgp over-expression in the brain. Furthermore, the interaction of CBZ with drugs that modulate both CYP3A4 and Pgp function such as verapamil is probably due to inhibition of CYP3A4 and not Pgp.
LanguageEnglish
Pages345-349
Number of pages5
JournalBritish Journal of Clinical Pharmacology
Volume51
Issue number4
DOIs
Publication statusPublished - 2001

Fingerprint

Carbamazepine
P-Glycoprotein
Glycoproteins
Cytochrome P-450 CYP3A
Rhodamine 123
Caco-2 Cells
Verapamil
Brain
Lymphocytes
Intestinal Mucosa
Anticonvulsants
Flow Cytometry
Fluorescence

Keywords

  • carbamazepine
  • p-glycoprotein
  • anticonvulsant carbamazepine
  • flow cytometry

Cite this

Owen, A., Pirmohamed, M., Tettey, J. N. A., Morgan, P., Chadwick, D., & Park, B. K. (2001). Carbamazepine is not a substrate for p-glycoprotein. British Journal of Clinical Pharmacology, 51(4), 345-349. https://doi.org/10.1046/j.1365-2125.2001.01359.x
Owen, A. ; Pirmohamed, M. ; Tettey, J.N.A. ; Morgan, P. ; Chadwick, D. ; Park, B.K. / Carbamazepine is not a substrate for p-glycoprotein. In: British Journal of Clinical Pharmacology. 2001 ; Vol. 51, No. 4. pp. 345-349.
@article{367ee446108543528052722223b2e45d,
title = "Carbamazepine is not a substrate for p-glycoprotein",
abstract = "Aims to determine whether the anticonvulsant carbamazepine (CBZ), a known CYP3A4 substrate, is also a substrate for the multidrug efflux transporter P-glycoprotein (Pgp). The role of Pgp in the transport of CBZ was assessed in three systems: (a) in mdr1a/1b(−/−) and wild-type mice after administration of 2 mg kg−1 and 20 mg kg−1, which served as a model for brain penetration; (b) in Caco-2 cells, an in vitro model of the intestinal epithelium that is known to express high Pgp levels; and (c) by flow cytometry in lymphocytes using rhodamine 123, a fluorescent substrate for PgP. Brain penetration of both doses of CBZ at 1 h and 4 h was comparable in wild-type and mdr1a/1b(−/−) mice. Transport across the Caco-2 cell monolayer was Pgp-independent, and was not affected by the Pgp inhibitor PSC-833. CBZ had no effect on rhodamine 123 efflux from lymphocytes, in contrast to verapamil, which increased fluorescence intensity fivefold. CBZ is not a substrate for Pgp. Its efficacy is unlikely to be affected by Pgp over-expression in the brain. Furthermore, the interaction of CBZ with drugs that modulate both CYP3A4 and Pgp function such as verapamil is probably due to inhibition of CYP3A4 and not Pgp.",
keywords = "carbamazepine, p-glycoprotein , anticonvulsant carbamazepine , flow cytometry",
author = "A. Owen and M. Pirmohamed and J.N.A. Tettey and P. Morgan and D. Chadwick and B.K. Park",
year = "2001",
doi = "10.1046/j.1365-2125.2001.01359.x",
language = "English",
volume = "51",
pages = "345--349",
journal = "British Journal of Clinical Pharmacology",
issn = "0306-5251",
number = "4",

}

Owen, A, Pirmohamed, M, Tettey, JNA, Morgan, P, Chadwick, D & Park, BK 2001, 'Carbamazepine is not a substrate for p-glycoprotein' British Journal of Clinical Pharmacology, vol. 51, no. 4, pp. 345-349. https://doi.org/10.1046/j.1365-2125.2001.01359.x

Carbamazepine is not a substrate for p-glycoprotein. / Owen, A.; Pirmohamed, M.; Tettey, J.N.A.; Morgan, P.; Chadwick, D.; Park, B.K.

In: British Journal of Clinical Pharmacology, Vol. 51, No. 4, 2001, p. 345-349.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Carbamazepine is not a substrate for p-glycoprotein

AU - Owen, A.

AU - Pirmohamed, M.

AU - Tettey, J.N.A.

AU - Morgan, P.

AU - Chadwick, D.

AU - Park, B.K.

PY - 2001

Y1 - 2001

N2 - Aims to determine whether the anticonvulsant carbamazepine (CBZ), a known CYP3A4 substrate, is also a substrate for the multidrug efflux transporter P-glycoprotein (Pgp). The role of Pgp in the transport of CBZ was assessed in three systems: (a) in mdr1a/1b(−/−) and wild-type mice after administration of 2 mg kg−1 and 20 mg kg−1, which served as a model for brain penetration; (b) in Caco-2 cells, an in vitro model of the intestinal epithelium that is known to express high Pgp levels; and (c) by flow cytometry in lymphocytes using rhodamine 123, a fluorescent substrate for PgP. Brain penetration of both doses of CBZ at 1 h and 4 h was comparable in wild-type and mdr1a/1b(−/−) mice. Transport across the Caco-2 cell monolayer was Pgp-independent, and was not affected by the Pgp inhibitor PSC-833. CBZ had no effect on rhodamine 123 efflux from lymphocytes, in contrast to verapamil, which increased fluorescence intensity fivefold. CBZ is not a substrate for Pgp. Its efficacy is unlikely to be affected by Pgp over-expression in the brain. Furthermore, the interaction of CBZ with drugs that modulate both CYP3A4 and Pgp function such as verapamil is probably due to inhibition of CYP3A4 and not Pgp.

AB - Aims to determine whether the anticonvulsant carbamazepine (CBZ), a known CYP3A4 substrate, is also a substrate for the multidrug efflux transporter P-glycoprotein (Pgp). The role of Pgp in the transport of CBZ was assessed in three systems: (a) in mdr1a/1b(−/−) and wild-type mice after administration of 2 mg kg−1 and 20 mg kg−1, which served as a model for brain penetration; (b) in Caco-2 cells, an in vitro model of the intestinal epithelium that is known to express high Pgp levels; and (c) by flow cytometry in lymphocytes using rhodamine 123, a fluorescent substrate for PgP. Brain penetration of both doses of CBZ at 1 h and 4 h was comparable in wild-type and mdr1a/1b(−/−) mice. Transport across the Caco-2 cell monolayer was Pgp-independent, and was not affected by the Pgp inhibitor PSC-833. CBZ had no effect on rhodamine 123 efflux from lymphocytes, in contrast to verapamil, which increased fluorescence intensity fivefold. CBZ is not a substrate for Pgp. Its efficacy is unlikely to be affected by Pgp over-expression in the brain. Furthermore, the interaction of CBZ with drugs that modulate both CYP3A4 and Pgp function such as verapamil is probably due to inhibition of CYP3A4 and not Pgp.

KW - carbamazepine

KW - p-glycoprotein

KW - anticonvulsant carbamazepine

KW - flow cytometry

U2 - 10.1046/j.1365-2125.2001.01359.x

DO - 10.1046/j.1365-2125.2001.01359.x

M3 - Article

VL - 51

SP - 345

EP - 349

JO - British Journal of Clinical Pharmacology

T2 - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

IS - 4

ER -